Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBT-NM108 to Reduce Chemotherapy-Induced Diarrhea in Metastatic Colon Cancer
NCT05296681Phase 2Recruiting
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NBT-NM108 in diarrhea (2 arms). Primary endpoints: Dose Intensity of Irinotecan administered at 8 weeks, Number of participants with treatment-related Adverse Events at 8 weeks and 1 more. Started May 2022; status: recruiting.
02
Drugs
NBT-NM108
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT05296681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296681.